Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (1) , e43-e50
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness AnalysisPLOS ONE, 2013
- Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled TrialsJournal of Clinical Oncology, 2013
- The role of generic medicines and biosimilars in oncology in low-income countriesAnnals of Oncology, 2013
- Comparisons of Health Care Systems in the United States, Germany and CanadaMateria Socio Medica, 2012
- Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myelomaHaematologica, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- How Should We Pay the Piper When He's Calling the Tune? On the Long-Term Affordability of Cancer Care in the United StatesJournal of Clinical Oncology, 2007
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005